抄録
(2R)-4'-O-Tetrahydropyranyladriamycin (THP) is a derivative of doxorubicin (adriamycin, ADM), a new antitumor antibiotic. THP has a stronger antitumor activity on L-1210 and other tumors implanted in mice but a lower cardiotoxicity than other anthracycline antibiotics1, 2).
The objective of this study was to examine toxic effects of THP in Beagle dogs with the intravenous administrations repeated for 13 weeks at daily dosages of 0.01, 0.02, 0.04 and 0.08mg/kg.
In addition, after completion of 13 weeks dosing, the animals received 0.02 and 0.04mg/kg of THP were subjected to recovery study for 5 weeks to monitor recovery from the toxic effects.
